Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
āļ.āļ. 2006 · John Wiley & Sons
eBook
391
āļŦāļāđāļē
reportāļāļ°āđāļāļāđāļĨāļ°āļĢāļĩāļ§āļīāļ§āđāļĄāđāđāļāđāļĢāļąāļāļāļēāļĢāļāļĢāļ§āļāļŠāļāļāļĒāļ·āļāļĒāļąāļ Â āļāļđāļāđāļāļĄāļđāļĨāđāļāļīāđāļĄāđāļāļīāļĄ
āđāļāļĩāđāļĒāļ§āļāļąāļ eBook āđāļĨāđāļĄāļāļĩāđ
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
āđāļāļĩāđāļĒāļ§āļāļąāļāļāļđāđāđāļāđāļ
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
āđāļŦāđāļāļ°āđāļāļ eBook āļāļĩāđ
āđāļŠāļāļāļāļ§āļēāļĄāđāļŦāđāļāļāļāļāļāļļāļāđāļŦāđāđāļĢāļēāļĢāļąāļāļĢāļđāđ
āļāđāļāļĄāļđāļĨāđāļāļāļēāļĢāļāđāļēāļ
āļŠāļĄāļēāļĢāđāļāđāļāļāđāļĨāļ°āđāļāđāļāđāļĨāđāļ
āļāļīāļāļāļąāđāļāđāļāļ Google Play Books āļŠāļģāļŦāļĢāļąāļ Android āđāļĨāļ° iPad/iPhone āđāļāļāļāļ°āļāļīāļāļāđāđāļāļĒāļāļąāļāđāļāļĄāļąāļāļīāļāļąāļāļāļąāļāļāļĩāļāļāļāļāļļāļ āđāļĨāļ°āļāđāļ§āļĒāđāļŦāđāļāļļāļāļāđāļēāļāđāļāļāļāļāļāđāļĨāļāđāļŦāļĢāļ·āļāļāļāļāđāļĨāļāđāđāļāđāļāļļāļāļāļĩāđ
āđāļĨāđāļāļāđāļāļāđāļĨāļ°āļāļāļĄāļāļīāļ§āđāļāļāļĢāđ
āļāļļāļāļāļąāļāļŦāļāļąāļāļŠāļ·āļāđāļŠāļĩāļĒāļāļāļĩāđāļāļ·āđāļāļāļēāļ Google Play āđāļāļĒāđāļāđāđāļ§āđāļāđāļāļĢāļēāļ§āđāđāļāļāļĢāđāđāļāļāļāļĄāļāļīāļ§āđāļāļāļĢāđāđāļāđ
eReader āđāļĨāļ°āļāļļāļāļāļĢāļāđāļāļ·āđāļāđ
āļŦāļēāļāļāđāļāļāļāļēāļĢāļāđāļēāļāļāļāļāļļāļāļāļĢāļāđ e-ink āđāļāđāļ Kobo eReader āļāļļāļāļāļ°āļāđāļāļāļāļēāļ§āļāđāđāļŦāļĨāļāđāļĨāļ°āđāļāļāđāļāļĨāđāđāļāļĒāļąāļāļāļļāļāļāļĢāļāđāļāļāļāļāļļāļ āđāļāļĢāļāļāļģāļāļēāļĄāļ§āļīāļāļĩāļāļēāļĢāļāļĒāđāļēāļāļĨāļ°āđāļāļĩāļĒāļāđāļāļĻāļđāļāļĒāđāļāđāļ§āļĒāđāļŦāļĨāļ·āļāđāļāļ·āđāļāđāļāļāđāļāļĨāđāđāļāļĒāļąāļ eReader āļāļĩāđāļĢāļāļāļĢāļąāļ
